CompletedNCT02517424
Vaporized Cannabis for Chronic Treatment-Resistant PTSD
About this title
Evaluating Safety and Efficacy of Cannabis in Participants With Chronic Posttraumatic Stress Disorder
Read the official source — NCT02517424Medication studyAges 18+Canada
Understand this study
Who was this study for?
Listed age limits: from 18 years.
- Listed locations
- KelownaSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateStarted: February 7, 2017
- Recruitment status
- Completed
- Enrollment listed in the registry
- 6
- Sponsor
- Tilray
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- Canada
- Age range
- Over 18 Years
- Official registry ID
- NCT02517424
- Official title
Show the full official title
Placebo-Controlled, Triple-Blind, Crossover Study of the Safety and Efficacy of Three Different Potencies of Vaporized Cannabis in 42 Participants With Chronic, Treatment-Resistant Posttraumatic Stress Disorder (PTSD)
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Kelowna
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Tilray.
Did this study involve medication?
Yes. The study involved medication, including High THC/Low CBD Cannabis, High THC/High CBD Cannabis and Low THC/Low CBD Cannabis.
Who was this study for?
Listed age limits: from 18 years.
